Illumina, Inc. (NASDAQ:ILMN) Receives Average Recommendation of "Hold" from Brokerages

Illumina, Inc. (NASDAQ:ILMN - Get Free Report) has earned a consensus rating of "Hold" from the nineteen research firms that are presently covering the company, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, nine have given a hold recommendation, eight have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average twelve-month price target among analysts that have issued ratings on the stock in the last year is $126.94.

Several brokerages have recently commented on ILMN. HSBC downgraded shares of Illumina from a "buy" rating to a "hold" rating and set a $100.00 price objective for the company. in a research report on Friday, February 28th. Canaccord Genuity Group lifted their price target on shares of Illumina from $87.00 to $99.00 and gave the company a "hold" rating in a research note on Wednesday, June 11th. Royal Bank Of Canada dropped their price objective on shares of Illumina from $128.00 to $112.00 and set an "outperform" rating on the stock in a report on Tuesday, April 8th. Citigroup reduced their target price on Illumina from $90.00 to $85.00 and set a "neutral" rating for the company in a research note on Monday, April 7th. Finally, Piper Sandler dropped their price target on Illumina from $190.00 to $185.00 and set an "overweight" rating on the stock in a research note on Thursday, May 15th.

Illumina Price Performance

ILMN stock opened at $90.26 on Thursday. The company has a quick ratio of 1.48, a current ratio of 1.86 and a debt-to-equity ratio of 0.63. The firm has a market cap of $14.29 billion, a price-to-earnings ratio of -14.87, a PEG ratio of 1.76 and a beta of 1.32. The company's fifty day simple moving average is $80.03 and its 200 day simple moving average is $101.80. Illumina has a 12-month low of $68.70 and a 12-month high of $156.66.

Illumina (NASDAQ:ILMN - Get Free Report) last announced its quarterly earnings data on Thursday, May 8th. The life sciences company reported $0.97 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.96 by $0.01. Illumina had a positive return on equity of 25.54% and a negative net margin of 22.25%. The company had revenue of $1.04 billion for the quarter, compared to the consensus estimate of $1.03 billion. During the same period in the previous year, the business earned $0.98 EPS. The firm's revenue was down 1.4% compared to the same quarter last year. On average, analysts expect that Illumina will post 4.51 earnings per share for the current year.

Insider Activity

In other news, CFO Ankur Dhingra purchased 6,100 shares of the firm's stock in a transaction dated Monday, May 12th. The shares were purchased at an average price of $81.21 per share, with a total value of $495,381.00. Following the completion of the acquisition, the chief financial officer now owns 24,906 shares in the company, valued at $2,022,616.26. This trade represents a 32.44% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through this hyperlink. Insiders own 2.60% of the company's stock.

Institutional Trading of Illumina

Hedge funds have recently added to or reduced their stakes in the business. Fourth Dimension Wealth LLC bought a new stake in shares of Illumina in the 4th quarter worth approximately $40,000. Bank Julius Baer & Co. Ltd Zurich bought a new stake in shares of Illumina during the 4th quarter valued at $45,000. Assetmark Inc. increased its stake in shares of Illumina by 954.8% in the 4th quarter. Assetmark Inc. now owns 327 shares of the life sciences company's stock worth $44,000 after acquiring an additional 296 shares in the last quarter. Rise Advisors LLC lifted its position in Illumina by 173.6% during the 1st quarter. Rise Advisors LLC now owns 353 shares of the life sciences company's stock valued at $28,000 after acquiring an additional 224 shares during the period. Finally, Lee Danner & Bass Inc. bought a new stake in Illumina during the fourth quarter worth about $48,000. 89.42% of the stock is owned by institutional investors.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.